Robert J. Glynn
Affiliations: | Boston University, Boston, MA, United States |
Area:
Biostatistics BiologyGoogle:
"Robert Glynn"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fralick M, Kim SC, Schneeweiss S, et al. (2020) Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. Bmj (Clinical Research Ed.). 370: m2812 |
| Ajala ON, Demler OV, Liu Y, et al. (2020) Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association. e016507 |
| Ridker PM, MacFadyen JG, Glynn RJ, et al. (2020) Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. European Heart Journal |
| Solomon DH, Glynn RJ, Karlson EW, et al. (2020) Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Annals of Internal Medicine |
| Dave C, Kim SC, Goldfine A, et al. (2020) 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy Diabetes. 69 |
| Dashti H, Liu Y, Glynn RJ, et al. (2020) Abstract P280: Revisiting CVD Risk Prediction Using Machine Learning Approaches: A Case Study Circulation. 141 |
| Ajala ON, Demler O, Liu Y, et al. (2020) Abstract P260: Determinants of Statin Response: A Secondary Analysis of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Circulation. 141 |
| Akinkuolie AO, Lawler PR, Chu AY, et al. (2019) Group IIA Secretory Phospholipase A and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. ATVBAHA118311894 |
| PATORNO E, PAWAR A, SCHNEEWEISS S, et al. (2019) 247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease Diabetes. 68: 247-OR |
| PATORNO E, KIM DH, PAWAR A, et al. (2019) 156-OR: Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults Diabetes. 68: 156-OR |